PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.
暂无分享,去创建一个
R. Jenq | M. V. D. van den Brink | M. Sadelain | C. Lezcano | Arnab Ghosh | G. Murphy | A. Hanash | L. Young | N. V. Singer | M. L. West | A. M. Holland | J. Tsai | Chen Liu | O. Penack | U. Rao | M. Sauer | Il-Kang Na | D. Sant’Angelo | N. Yim | Yildirim Dogan | Hae Lee | Natalie V. Singer | Mallory L. West | A. Holland
[1] D. Marin,et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. , 2012, Blood.
[2] C. Anasetti,et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. , 2011, Blood.
[3] J. Wolchok,et al. Altered Development of NKT Cells, γδ T Cells, CD8 T Cells and NK Cells in a PLZF Deficient Patient , 2011, PloS one.
[4] A. Sepulveda,et al. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. , 2011, The Journal of clinical investigation.
[5] A. Luster,et al. PLZF induces an intravascular surveillance program mediated by long-lived LFA-1–ICAM-1 interactions , 2011, The Journal of experimental medicine.
[6] Michael G. Constantinides,et al. Promyelocytic Leukemia Zinc Finger Turns on the Effector T Cell Program without Requirement for Agonist TCR Signaling , 2011, The Journal of Immunology.
[7] M. Shlomchik,et al. A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. , 2011, Blood.
[8] R. Luong,et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. , 2011, Blood.
[9] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[10] W. Leonard,et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. , 2010, Blood.
[11] B. McColl,et al. Interleukin-1 drives cerebrovascular inflammation via MAP kinase-independent pathways. , 2010, Current neurovascular research.
[12] Christopher G. King,et al. Absence of P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Ameliorates Experimental Graft-versus-Host Disease , 2010, The Journal of Immunology.
[13] K. Nichols,et al. PLZF Induces the Spontaneous Acquisition of Memory/Effector Functions in T Cells Independently of NKT Cell-Related Signals , 2010, The Journal of Immunology.
[14] R. Jenq,et al. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer , 2010, Nature Reviews Cancer.
[15] T. Yi,et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] K. Welte,et al. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. , 2009, Blood.
[17] Lieping Chen,et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. , 2009, Blood.
[18] Christopher G. King,et al. IL-17 contributes to CD4-mediated graft-versus-host disease. , 2009, Blood.
[19] Christopher G. King,et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. , 2008, Blood.
[20] T. Rülicke,et al. The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells , 2008, Proceedings of the National Academy of Sciences.
[21] O. Lantz,et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. , 2008, Immunity.
[22] P. Pandolfi,et al. The BTB–zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions , 2008, Nature Immunology.
[23] C. Klein,et al. Cytotoxic T Cells Reactive to an Immunodominant Leukemia-associated Antigen can be Specifically Primed and Expanded by Combining a Specific Priming Step With Nonspecific Large-scale Expansion , 2008, Journal of immunotherapy.
[24] M. V. D. van den Brink,et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.
[25] M. V. D. van den Brink,et al. CCR2 is required for CD8-induced graft-versus-host disease. , 2005, Blood.
[26] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[27] M. V. D. van den Brink,et al. Fas-Deficient lpr Mice Are More Susceptible to Graft-Versus-Host Disease1 , 2000, The Journal of Immunology.
[28] K. Oshimi,et al. Differential Effects of Anti-Fas Ligand and Anti-Tumor Necrosis Factor α Antibodies on Acute Graft-Versus-Host Disease Pathologies , 1998 .
[29] K. Oshimi,et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. , 1998, Blood.